Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

ward to further evaluating the correlation between rash and clinical activity, as well as alternate dosing schedules of CR011-vcMMAE," commented Dr. Hwu.

CuraGen is currently enrolling patients into a Phase I portion of this trial to evaluate more frequent dosing schedules of CR011-vcMMAE, including a weekly and a two out of every three-week regimen, to explore if more frequent administration can provide additional activity in patients with metastatic melanoma. CR011-vcMMAE is also being studied in an ongoing Phase II trial in patients with metastatic breast cancer who have received previous chemotherapy. CuraGen anticipates providing updated data from the ongoing melanoma and breast cancer studies in the first half of 2009.

"While we continue to finalize data from this study, develop data from more frequent dosing in patients with metastatic melanoma and from the Phase II study in patients with breast cancer, we will be engaging in discussions with potential partners as we develop plans for the advanced stages of development," added Dr. Shannon. "The goal of a partnership will be to support the financial, development and commercial resources that will be required in advanced development, improving the risk profile to CuraGen shareholders while maintaining upside potential."

In addition to M. D. Anderson, other sites participating in the melanoma trial include Yale Cancer Center, New Haven, CT; The Angeles Clinic and Research Institute, Santa Monica, CA; and New York University Medical Center, New York, NY.

Reprints of the presentation will be made available on CuraGen's website at http://www.curagen.com or can be requested by emailing info@curagen.com.

Conference Call Details and Dial-in Information

Date: Monday, November 3, 2008

Time: 11:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
... Reportlinker.com announces that a new market research ... Merck & Co., Inc.: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast performance ... sector. The profile encompasses global company strategy, portfolio ...
Cached Medicine Technology:Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... ... , ... The condition where veins are enlarged and gnarled is known as ... discomfort. Those who spend a lot of time on their feet and standing are ... what it can to create awareness and provide a cure in observance of Senior ...
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... events, from tornados, floods, fires and hurricanes, researchers at ... physiological changes associated with aging and the presence of ... or injury, even death, during a disaster. Investigators ... of 86, who were evacuated for five days due ...
... France, 21 October 2011 A pioneering educational resource, ... chronic hepatitis B, was launched today at an annual ... 26 patient advocacy groups from 14 countries and regions ... ("Patients and Professionals Acting Together for Hepatitis B") programme ...
... FRIDAY, Oct. 21 (HealthDay News) -- Elevated levels of hormones ... number of different elevated hormones rises, so does the risk, ... Women,s Hospital and Harvard Medical School in Boston examined levels ... collected from nurses up to nine years before their health ...
... a higher burden of multiple, large-joint osteoarthritis (OA), and may ... OA." African Americans were also more likely to have knee ... than Caucasians according to the findings reported today in ... College of Rheumatology (ACR). OA is the most ...
... -- The number of American women with precancerous cells ... 2000, and the increase has led to the release Thursday ... Cancer of the vulva -- the outside of the genital ... (HPV), which also causes cervical cancer. The precancerous condition -- ...
... , THURSDAY, Oct. 20 (HealthDay News) -- Most Americans consume ... needed to reduce the amount of dietary salt, according to ... of sodium consumption are associated with increased risk of high ... experts warn. In general, people aged 2 years and ...
Cached Medicine News:Health News:Elderly long-term care residents suffer cognitively during disasters 2Health News:'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched 2Health News:'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched 3Health News:Breast Cancer Risk May Rise With High Hormone Levels 2Health News:More African-Americans burdened by osteoarthritis in multiple large joints 2Health News:Rise in Vulvar Precancers Leads to New Guidelines 2Health News:U.S. Diet Still Has Too Much Salt, CDC Warns 2
Cannulated Interference Screws...
Cannulated Interference Screws...
... new WHITESTAR Technology, which transforms traditional ultrasound ... reduces the amount of phaco energy directed ... ultrasound cutting efficiency. Surgeons have ... and efficiently to the phaco tip, in ...
... NATURE'S TEARS is an all-natural moisturizing mist ... assistance of Dr. William Mathers, from Oregon ... Mathers' study of NATURE'S TEARS (2000) and ... the mist doubled the moisture volume of ...
Medicine Products: